Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1292
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Angioedema late in the course of adjuvant nivolumab therapy for melanoma
Atul Ratra,Constantin A Dasanu
Journal of Oncology Pharmacy Practice.2019;()107815521988118
[DOI]
2Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report
El Ali Ziad,Verset Laurine
Clinical Oncology and Research.2019;()1
[DOI]
3The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
Bradley D. Menz,Jacinta L. Johnson,Davina F. Gillard,William Chong,Michael B. Ward
Journal of Pharmacy Practice.2019;()089719001987293
[DOI]
4Durvalumab in cancer medicine: a comprehensive review
Juliana Alvarez-Argote,Constantin A. Dasanu
Expert Opinion on Biological Therapy.2019;19(9)927
[DOI]
5The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Danilo Rocco,Luigi Della Gravara,Ciro Battiloro,Cesare Gridelli
Expert Review of Anticancer Therapy.2019;19(7)561
[DOI]
6Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Ronald Anderson,Annette J. Theron,Bernardo L. Rapoport
Frontiers in Immunology.2019;10(7)561
[DOI]
Feedback
Subscribe

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal